1. Administration USFaD. Hematology/oncology (cancer) approvals & safety notifications [Available from:
https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications
.
2. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121–43.
3. FDA. Rituximab [Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf
.
4. Hernandez-Ilizaliturri FJ, Czuczman MS. Understanding the mechanisms of resistance to rituximab: paving the road for the development of therapeutic strategies to overcome rituximab-resistance. In: Bonavida B, editor. Resistance to immunotherapeutic antibodies in cancer. 2. New York: Springer; 2013.
5. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol. 2002;22(3):124–30.